Aldosterone breakthrough during angiotensin receptor blocker use: more questions than answers?
作者信息
Navaneethan Sankar D, Bravo Emmanuel L
机构信息
Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, †Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, Ohio.
出版信息
Clin J Am Soc Nephrol. 2013 Oct;8(10):1637-9. doi: 10.2215/CJN.07370713. Epub 2013 Aug 8.
Abstract
摘要
相似文献
1
Aldosterone breakthrough during angiotensin receptor blocker use: more questions than answers?血管紧张素受体阻滞剂使用期间的醛固酮突破：问题多于答案？
Clin J Am Soc Nephrol. 2013 Oct;8(10):1637-9. doi: 10.2215/CJN.07370713. Epub 2013 Aug 8.
2
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy.2 型糖尿病显性肾病患者血管紧张素 II 受体阻断后醛固酮突破的相关决定因素和变化。
Clin J Am Soc Nephrol. 2013 Oct;8(10):1694-701. doi: 10.2215/CJN.06960712. Epub 2013 Aug 8.
3
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Am J Hypertens. 2007 Dec;20(12):1329-33. doi: 10.1016/j.amjhyper.2007.09.001.
4
Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.基于社区的 2 型糖尿病患者的肾素-血管紧张素-醛固酮系统阻断和尿白蛋白排泄：弗里曼特尔糖尿病研究。
Diabet Med. 2011 Jul;28(7):849-55. doi: 10.1111/j.1464-5491.2011.03230.x.
5
Renoprotective effects of renin-angiotensin-aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis.肾素-血管紧张素-醛固酮系统阻滞剂在2型糖尿病中的肾脏保护作用：在网络荟萃分析中解读多重治疗比较
Diabetologia. 2012 Sep;55(9):2547-8; author reply 2549-50. doi: 10.1007/s00125-012-2619-9. Epub 2012 Jun 23.
6
Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.2型糖尿病肾病中肾素-血管紧张素-醛固酮系统的双重阻断
Chin Med J (Engl). 2016 Jan 5;129(1):81-7. doi: 10.4103/0366-6999.172599.
7
ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.用于治疗糖尿病肾病的血管紧张素转换酶抑制剂或血管紧张素Ⅱ受体拮抗剂：激烈的争论仍在继续
Diabetes Metab Syndr. 2012 Oct-Dec;6(4):215-7. doi: 10.1016/j.dsx.2012.08.005. Epub 2012 Sep 7.
8
The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy.肾素-血管紧张素-醛固酮系统抑制剂对伴有和不伴有早期糖尿病肾病的 1 型和 2 型糖尿病患者的影响。
Kidney Int. 2012 Apr;81(7):674-83. doi: 10.1038/ki.2011.413. Epub 2011 Dec 21.
9
Detecting and controlling diabetic nephropathy: what do we know?检测和控制糖尿病肾病：我们了解多少？
Cleve Clin J Med. 2013 Apr;80(4):209-17. doi: 10.3949/ccjm.80gr.12006.
10
You are what you eat: dietary salt intake and renin-angiotensin blockade in diabetic nephropathy.饮食中的盐与糖尿病肾病中的肾素-血管紧张素阻断。
Kidney Int. 2012 Aug;82(3):257-9. doi: 10.1038/ki.2012.148.
引用本文的文献
1
Aldosterone in Chronic Kidney Disease.慢性肾脏病中的醛固酮
Biomedicines. 2025 Aug 26;13(9):2081. doi: 10.3390/biomedicines13092081.
2
Efficacy of Esaxerenone Plus a Renin-Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis.依普利酮联合肾素-血管紧张素系统抑制剂或钙通道阻滞剂治疗夜间高血压的疗效：一项事后分析
Am J Hypertens. 2025 Jul 15;38(8):605-611. doi: 10.1093/ajh/hpaf048.
3
Potential of Modulating Aldosterone Signaling and Mineralocorticoid Receptor with microRNAs to Attenuate Diabetic Kidney Disease.利用 microRNAs 调节醛固酮信号和盐皮质激素受体以减轻糖尿病肾病的潜力。
Int J Mol Sci. 2024 Jan 10;25(2):869. doi: 10.3390/ijms25020869.
4
The Effect of Aldosterone on Cardiorenal and Metabolic Systems.醛固酮对心肾及代谢系统的影响。
Int J Mol Sci. 2023 Mar 11;24(6):5370. doi: 10.3390/ijms24065370.
5
Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients.80 岁以上心力衰竭患者中添加盐皮质激素受体拮抗剂的预后影响。
ESC Heart Fail. 2020 Oct;7(5):2711-2724. doi: 10.1002/ehf2.12862. Epub 2020 Aug 28.
6
miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated aldosterone-induced renal fibrosis in mice with diabetes.来自肾小管上皮细胞的富含miR-196b-5p的细胞外囊泡介导了糖尿病小鼠中醛固酮诱导的肾纤维化。
BMJ Open Diabetes Res Care. 2020 Jul;8(1). doi: 10.1136/bmjdrc-2019-001101.
7
Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling.滋肾活络方通过干预醛固酮突破、影响小窝蛋白-1/盐皮质激素受体共定位及下游细胞外信号调节激酶信号通路增强血管紧张素转换酶抑制剂对高血压左心室肥厚的治疗作用。
Front Pharmacol. 2020 Apr 3;11:383. doi: 10.3389/fphar.2020.00383. eCollection 2020.
本文引用的文献
1
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy.2 型糖尿病显性肾病患者血管紧张素 II 受体阻断后醛固酮突破的相关决定因素和变化。
Clin J Am Soc Nephrol. 2013 Oct;8(10):1694-701. doi: 10.2215/CJN.06960712. Epub 2013 Aug 8.
2
Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.血浆醛固酮水平与心血管死亡率升高相关：路德维希港风险和心血管健康（LURIC）研究。
Eur Heart J. 2010 May;31(10):1237-47. doi: 10.1093/eurheartj/ehq019. Epub 2010 Mar 2.
3
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.在糖尿病肾病中，于最大程度的血管紧张素转换酶抑制基础上加用血管紧张素受体阻滞剂或盐皮质激素拮抗剂。
J Am Soc Nephrol. 2009 Dec;20(12):2641-50. doi: 10.1681/ASN.2009070737. Epub 2009 Nov 19.
4
Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.螺内酯对早期慢性肾脏病左心室质量和主动脉僵硬度的影响：一项随机对照试验
J Am Coll Cardiol. 2009 Aug 4;54(6):505-12. doi: 10.1016/j.jacc.2009.03.066.
5
Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.醛固酮拮抗剂预防慢性肾脏病进展的系统评价与荟萃分析
Clin J Am Soc Nephrol. 2009 Mar;4(3):542-51. doi: 10.2215/CJN.04750908. Epub 2009 Mar 4.
6
The aggravating mechanisms of aldosterone on kidney fibrosis.醛固酮对肾纤维化的加重机制。
J Am Soc Nephrol. 2008 Aug;19(8):1459-62. doi: 10.1681/ASN.2007101079. Epub 2008 Jun 11.
7
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.替米沙坦在降低糖尿病肾病患者蛋白尿方面比氯沙坦更有效。
Kidney Int. 2008 Aug;74(3):364-9. doi: 10.1038/ki.2008.204. Epub 2008 May 21.
8
The incidence and implications of aldosterone breakthrough.醛固酮突破的发生率及影响
Nat Clin Pract Nephrol. 2007 Sep;3(9):486-92. doi: 10.1038/ncpneph0575.
9
Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.一项双盲、安慰剂对照研究，旨在探讨醛固酮受体拮抗剂螺内酯对持续蛋白尿且正在接受长期血管紧张素转换酶抑制剂治疗（无论是否联用血管紧张素II受体阻滞剂）的患者的疗效。
Clin J Am Soc Nephrol. 2006 Mar;1(2):256-62. doi: 10.2215/CJN.01040905. Epub 2006 Feb 1.
10
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.螺内酯对慢性肾脏病患者蛋白尿和肾功能的长期影响。
Kidney Int. 2006 Dec;70(12):2116-23. doi: 10.1038/sj.ki.5001854. Epub 2006 Oct 11.
Zotero 插件